| Registry | NCT07189689 |
|---|---|
| Status | Not yet recruiting |
| Study type | Observational |
| Enrollment | 2000 (Estimated) |
| Sponsor | University of Oxford (Other); collaborators: Newcastle University, University of Nottingham, University of Exeter, University of Southampton, University of Birmingham, University of Manchester, University of Liverpool, Avon and Wiltshire Mental Health Partnership NHS Trust, Cambridgeshire and Peterborough NHS Foundation Trust, University of Cambridge, Cardiff University, Cardiff and Vale University Health Board, University of Edinburgh, University of Glasgow, University College, London, Sheffield Health and Social Care NHS Foundation Trust, King's College London, Imperial College London, Oxford Health NHS FT, Cumbria, Northumberland, Tyne and Wear NHS FT, South London and Maudsley NHS FT, Nottinghamshire Healthcare NHS FT, Devon Partnership Trust, Hampshire and Isle of Wight Health NHS FT, Birmingham and Solihull Mental Health NHS Trust, Mersey Care NHS FT, NHS Lothian, NHS Greater Glasgow and Clyde, Camden & Islington NHS FT, West London NHS FT, Central and North West London NHS FT |
| Conditions | Depression - Major Depressive Disorder, Depression Bipolar, Treatment Resistant Depression |
| Dates | start 2025-10-01 (estimated), primary completion 2028-01-31 (estimated), completion 2028-01-31 (estimated), first posted 2025-09-24, last updated 2025-10-03 |
| Locations | 1 site in United Kingdom |
Related Papers Related Patents Related Grants Related Experts
All trials for Depression - Major Depressive Disorder All trials for Depression Bipolar
The current study aims to understand why some people with depression respond to treatment and others do not, using markers of clinical symptoms, both clinician reported outcome measures and patient reported outcome measures, demographic information, cognitive function, genetic sequence information (genomic), chemical measures of metabolism (metabolomic), protein makeup (proteomic) and the body's natural defence system (immune/inflammatory markers) together with collections of cells that will facilitate new research to drive improvements in diagnosis and treatment of mood disorders that may be proving difficult to treat. This will allow future clinical trials within the NHS, academia and industry to drive forward new approaches and treatments.
Participants who provide consent for re-contact for future treatment trials and other research studies have the potential to benefit from this with participation in experimental studies and clinical trials associated with improved patient outcomes. Overall, the cohort will generally support greater access to research opportunities for a wider population of people.
Sex: All, ages: 18 Years to any
Inclusion Criteria: * Those aged 18 and above * Primary clinical diagnosis of MDD or bipolar disorder based on DSM-5/ICD-11 diagnostic criteria * Participant is willing and able to give informed consent for participation in the study * Possesses sufficient command of the English language required to complete study requirements, as assessed by the study team Exclusion Criteria: * Inability to complete study activities as assessed by the study team * Presentation requires immediate emergency treatment * Presentation requires clinical input not available within the research clinic
| Facility | City | Country | Status |
|---|---|---|---|
| Clinical Research Facility, Warneford Hospital | Oxford | United Kingdom |